Volume 271,
Number 6,
Issue of February 9, 1996 pp. 2966-2971
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Rational
Design of Granulocyte-Macrophage Colony-stimulating Factor Antagonist
Peptides
(Received for publication, September 20, 1995; and in revised form, November 7,
1995)
Cristina
Monfardini
, ,
Thomas
Kieber-Emmons
,
Donald
Voet
,
A.
Paul
Godillot
, ,
David
B.
Weiner
, , ,
William
V.
Williams
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a
member of the four-helix bundle family of cytokines/growth factors
which exhibit several activities. It is a hematopoietic growth factor,
a cytokine involved in inflammatory and immune processes, an adjunct
for cancer therapy, and an anti-tumor immunomodulator. Studies of
interactions between GM-CSF and its receptor and identification of
small peptides presenting binding capacity to the receptor are
important goals for the development of GM-CSF analogs. Here we describe
the study of two cyclic peptides, 1785 and 1786, developed based on
structural analysis of the GM-CSF region mimicked by anti-anti-GM-CSF
recombinant antibody 23.2. These peptides were designed to structurally
mimic the positions of specific residues on the B and C helices of
human GM-CSF implicated in receptor binding and bioactivity. Both 1785
and 1786 were specifically recognized by polyclonal anti-GM-CSF
antibody (stronger for 1786 than 1785). 1786 also competitively
inhibited binding of GM-CSF to the GM-CSF receptor on HL-60 cells and
demonstrated antagonist bioactivity, as shown by its reversal of
GM-CSF's ability to inhibit apoptosis of the GM-CSF-dependent
cell line MO7E. These studies support the role of residues on the
GM-CSF B and C helices in receptor binding and bioactivity and suggest
strategies for mimicking binding sites on four-helix bundle proteins
with cyclic peptides.